Inhibiting mycobacterium tuberculosis within and without

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 371, Issue 1707, 2016, Pages

  Cole, Stewart T ^a  

^a EPFL   (Switzerland)

Author keywords

Antibiotics; Drug discovery; Drug resistance; Phagocytes; Tuberculosis

Indexed keywords

ANTIBIOTICS; BACTERIUM; DRUG DEVELOPMENT; DRUG RESISTANCE; INHIBITION; METABOLISM; PIPELINE; SECRETION; TUBERCULOSIS; VIRULENCE;

BACILLI (CLASS); MYCOBACTERIUM TUBERCULOSIS;

TUBERCULOSTATIC AGENT;

DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84988811913     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2015.0506     Document Type: Review

References (78)

1. Hopwood DA. 2007 Streptomyces in nature and medicine: the antibiotic makers. Oxford, UK: Oxford University Press.
2. Lewis K. 2012 Antibiotics: recover the lost art of drug discovery. Nature 485, 439-440. (doi:10.1038/485439a)
3. Cole ST. 2014 Who will develop new antibacterial agents? Phil. Trans. R. Soc. B 369, 20130430. (doi:10.1098/rstb.2013.0430)
4. WHO. 2015 Global tuberculosis report 2015. Geneva, Switzerland: World Health Organization.
5. Cole ST et al. 1998 Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544. (doi:10.1038/31159)
6. Diacon AH et al. 2012 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380, 986-993. (doi:10.1016/S0140-6736(1261080-0)
7. Zumla A, Nahid P, Cole ST. 2013 Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404. (doi:10.1038/nrd4001)
8. Nuermberger EL, Yoshimatsu T, Tyagi S, O’Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. 2004 Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169, 421-426. (doi:10.1164/rccm.200310-1380OC)
9. Rustomjee R et al. 2008 A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12, 128-138.
10. Gillespie SH et al. 2014 Four-month moxifloxacinbased regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577-1587. (doi:10.1056/NEJMoa1407426)
11. Merle CS et al. 2014 A four-month gatifloxacincontaining regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588-1598. (doi:10.1056/NEJMoa1315817)
12. Jindani A et al. 2014 High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599-1608. (doi:10.1056/NEJMoa1314210)
13. Warner DF, Mizrahi V. 2014 Shortening treatment for tuberculosis-to basics. N. Engl. J. Med. 371, 1642-1643. (doi:10.1056/NEJMe1410977)
14. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007 Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40. (doi:10.1038/nrd2201)
15. Fernandez P, Saint-Joanis B, Barilone N, Jackson M, Gicquel B, Cole ST, Alzari PM. 2006 The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth. J. Bacteriol. 188, 7778-7784. (doi:10.1128/JB.00963-06)
16. Sams-Dodd F. 2005 Target-based drug discovery: is something wrong? Drug Discov. Today 10, 139-147. (doi:10.1016/S1359-6446(0403316-1)
17. Stover CK et al. 2000 A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966. (doi:10.1038/35016103)
18. Andries K et al. 2005 A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227. (doi:10.1126/science.1106753)
19. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006 OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3, e466. (doi:10.1371/journal.pmed.0030466)
20. Sacksteder KA, Protopopova M, Barry 3rd CE, Andries K, Nacy CA. 2012 Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 7, 823-837. (doi:10.2217/fmb.12.56)
21. Pethe K et al. 2013 Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19, 1157-1160. (doi:10.1038/nm.3262)
22. Makarov V et al. 2014 Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 6, 372-383. (doi:10.1002/emmm.201303575)
23. Lechartier B, Rybniker J, Zumla A, Cole ST. 2014 Tuberculosis drug discovery in the post-postgenomic era. EMBO Mol. Med. 6, 158-168. (doi:10.1002/emmm.201201772)
24. Ballell L et al. 2013 Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem 8, 313-321. (doi:10.1002/cmdc.201200428)
25. Stanley SA et al. 2012 Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377-1384. (doi:10.1021/cb300151m)
26. Ioerger TR et al. 2013 Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONE 8, e75245. (doi:10.1371/journal.pone.0075245)
27. Makarov V et al. 2009 Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801-804. (doi:10.1126/science.1171583)
28. Magnet S et al. 2010 Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 90, 354-360. (doi:10.1016/j.tube.2010.09.001)
29. Christophe T et al. 2009 High content screening identifies decaprenyl-phosphoribose 2’ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645. (doi:10.1371/journal.ppat.1000645)
30. Landge S et al. 2015 Discovery of benzothiazoles as antimycobacterial agents: synthesis, structureactivity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphorylb-D-ribose 2’-oxidase. Bioorg. Med. Chem. 23, 7694-7710. (doi:10.1016/j.bmc.2015.11.017)
31. Wang F et al. 2013 Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc. Natl Acad. Sci. USA 110, E2510-E2517. (doi:10.1073/pnas.1309171110)
32. Neres J et al. 2015 2-Carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem. Biol. 10, 705-714. (doi:10.1021/cb5007163)
33. Chatterji M et al. 2014 1,4-Azaindole, a potential drug candidate for treatment of tuberculosis. Antimicrob. Agents Chemother. 58, 5325-5331. (doi:10.1128/AAC.03233-14)
34. Panda M et al. 2014 Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J. Med. Chem. 57, 4761-4771. (doi:10.1021/jm5002937)
35. La Rosa V et al. 2012 MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56, 324-331. (doi:10.1128/AAC.05270-11)
36. Remuinan MJ et al. 2013 Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6’,7’-dihydrospiro[piperidine-4,4’-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS ONE 8, e60933. (doi:10.1371/journal.pone.0060933)
37. Rao SP et al. 2013 Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci. Transl. Med. 5, 214ra168. (doi:10.1126/scitranslmed.3007355)
38. Lun S et al. 2013 Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nat. Commun. 4, 2907. (doi:10.1038/ncomms3907)
39. Grzegorzewicz AE et al. 2012 Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8, 334-341. (doi:10.1038/nchembio.794)
40. Tantry SJ et al. 2015 Whole cell screen based identification of spiropiperidines with potent antitubercular properties. Bioorg. Med. Chem. Lett. 25, 3234-3245. (doi:10.1016/j.bmcl.2015.05.087)
41. Maddry JA et al. 2009 Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis 89, 354-363. (doi:10.1016/j.tube.2009.07.006)
42. Ananthan S et al. 2009 High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis 89, 334-353. (doi:10.1016/j.tube.2009.05.008)
43. Wilson R et al. 2013 Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat. Chem. Biol. 9, 499-506. (doi:10.1038/nchembio.1277)
44. Abrahams KA et al. 2012 Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS ONE 7, e52951. (doi:10.1371/journal.pone.0052951)
45. Moraski GC et al. 2013 Advancement of imidazo[1,2-]pyridines with improved pharmacokinetics and nanomolar activity against. ACS Med. Chem. Lett. 4, 675-679. (doi:10.1021/ml400088y)
46. Khoje AD, Charnock C, Wan B, Franzblau S, Gundersen LL. 2011 Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles. Bioorg. Med. Chem. 19, 3483-3491. (doi:10.1016/j.bmc.2011.04.023)
47. Arora K et al. 2014 Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 6962-6965. (doi:10.1128/AAC.03486-14)
48. Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST. 2015 Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat. Commun. 6, 7659. (doi:10.1038/ncomms8659)
49. Mikusova K, Makarov V, Neres J. 2014 DprE1-from the discovery to the promising tuberculosis drug target. Curr. Pharmaceut. Des. 20, 4379-4403. (doi:10.2174/138161282027140630122724)
50. Kolly GS et al. 2014 Assessing the essentiality of the decaprenyl-phospho-D-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. Mol. Microbiol. 92, 194-211. (doi:10.1111/mmi.12546)
51. Li W et al. 2014 Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 6413-6423. (doi:10.1128/AAC.03229-14)
52. Brodin P, Christophe T. 2011 High-content screening in infectious diseases. Curr. Opin. Chem. Biol. 15, 534-539. (doi:10.1016/j.cbpa.2011.05.023)
53. Gavalda S et al. 2014 The polyketide synthase Pks13 catalyzes a novel mechanism of lipid transfer in mycobacteria. Chem. Biol. 21, 1660-1669. (doi:10.1016/j.chembiol.2014.10.011)
54. Goldman RC. 2013 Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis 93, 569-588. (doi:10.1016/j.tube.2013.09.003)
55. Feng X et al. 2015 Antiinfectives targeting enzymes and the proton motive force. Proc. Natl Acad. Sci. USA 112, E7073-E7082. (doi:10.1073/pnas.1521988112)
56. Li K et al. 2014 Multitarget drug discovery for tuberculosis and other infectious diseases. J. Med. Chem. 57, 3126-3139. (doi:10.1021/jm500131s)
57. Brecik M et al. 2015 DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization. ACS Chem. Biol. 10, 1631-1636. (doi:10.1021/acschembio.5b00237)
58. Meniche X, Otten R, Siegrist MS, Baer CE, Murphy KC, Bertozzi CR, Sassetti CM. 2014 Subpolar addition of new cell wall is directed by DivIVA in mycobacteria. Proc. Natl Acad. Sci. USA 111, E3243-E3251. (doi:10.1073/pnas.1402158111)
59. Carel C, Nukdee K, Cantaloube S, Bonne M, Diagne CT, Laval F, Daffe M, Zerbib D. 2014 Mycobacterium tuberculosis proteins involved in mycolic acid synthesis and transport localize dynamically to the old growing pole and septum. PLoS ONE 9, e97148. (doi:10.1371/journal.pone.0097148)
60. Zumla A et al. 2015 Towards host-directed therapies for tuberculosis. Nat. Rev. Drug Discov. 14, 511-512. (doi:10.1038/nrd4696)
61. Christophe T, Ewann F, Jeon HK, Cechetto J, Brodin P. 2010 High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. Future Med. Chem. 2, 1283-1293. (doi:10.4155/fmc.10.223)
62. VanderVen BC et al. 2015 Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium’s metabolism is constrained by the intracellular environment. PLoS Pathog. 11, e1004679. (doi:10.1371/journal.ppat.1004679)
63. Chen JM, Pojer F, Blasco B, Cole ST. 2010 Towards anti-virulence drugs targeting ESX-1 mediated pathogenesis of Mycobacterium tuberculosis. Drug Discov. Today 7, e25-e31. (doi:10.1016/j.ddmec.2010.09.002)
64. Bitter W et al. 2009 Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog. 5, e1000507. (doi:10.1371/journal.ppat.1000507)
65. Houben EN, Korotkov KV, Bitter W. 2014 Take five—type VII secretion systems of Mycobacteria. Biochim. Biophys. Acta 1843, 1707-1716. (doi:10.1016/j.bbamcr.2013.11.003)
66. Simeone R, Bobard A, Lippmann J, Bitter W, Majlessi L, Brosch R, Enninga J. 2012 Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog. 8, e1002507. (doi:10.1371/journal.ppat.1002507)
67. Simeone R, Bottai D, Brosch R. 2009 ESX/type VII secretion systems and their role in host-pathogen interaction. Curr. Opin. Microbiol. 12, 4-10. (doi:10.1016/j.mib.2008.11.003)
68. Simeone R, Bottai D, Frigui W, Majlessi L, Brosch R. 2015 ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection. Tuberculosis 95(Suppl. 1, S150-S154. (doi:10.1016/j.tube.2015.02.019)
69. Simeone R, Sayes F, Song O, Groschel MI, Brodin P, Brosch R, Majlessi L. 2015 Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. PLoS Pathog. 11, e1004650. (doi:10.1371/journal.ppat.1004650)
70. Stanley SA, Johndrow JE, Manzanillo P, Cox JS. 2007 The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 178, 3143-3152. (doi:10.4049/jimmunol.178.5.3143)
71. Rybniker J et al. 2014 Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host Microbe 16, 538-548. (doi:10.1016/j.chom.2014.09.008)
72. Pang X, Samten B, Cao G, Wang X, Tvinnereim AR, Chen XL, Howard ST. 2013 MprAB regulates the espA operon in Mycobacterium tuberculosis and modulates ESX-1 function and host cytokine response. J. Bacteriol. 195, 66-75. (doi:10.1128/JB.01067-12)
73. Wassermann R et al. 2015 Mycobacterium tuberculosis differentially activates cGAS-and inflammasome-dependent intracellular immune responses through ESX-1. Cell Host Microbe 17, 799-810. (doi:10.1016/j.chom.2015.05.003)
74. Johnson BK, Colvin CJ, Needle DB, Mba Medie F, Champion PA, Abramovitch RB. 2015 The carbonic anhydrase inhibitor ethoxzolamide inhibits the Mycobacterium tuberculosis PhoPR regulon and Esx-1 secretion and attenuates virulence. Antimicrob. Agents Chemother. 59, 4436-4445. (doi:10.1128/AAC.00719-15)
75. Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, Huygen K, Hernandez-Pando R, Thole J, Behr M, Gicquel B, Martin C. 2008 PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS ONE 3, e3496. (doi:10.1371/journal.pone.0003496)
76. Frigui W et al. 2008 Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog. 4, e33. (doi:10.1371/journal.ppat.0040033)
77. Tameris MD et al. 2013 Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028. (doi:10.1016/S0140-6736(1360177-4)
78. Mockenhaupt FP et al. 2016 Profile of illness in Syrian refugees: a GeoSentinel analysis, 2013 to 2015. Euro Surveill. 21, 30160. (doi:10.2807/1560-7917.ES.2016.21.10.30160)